Sponsored Videos

Emily Schirmer, Catalent, explains how to accelerate the path to first-in-human trials as biologics pipelines grow more complex and timelines tighten.

Dr. Patrick Meyer, Global Head of Business Development at Rentschler Biopharma, outlines the deciding factors biotechs should consider when selecting a contract development and manufacturing organization (CDMO) partner.

Campbell Bunce, CSO, Abzena, explains their integrated drug development model that combines front-end R&D with process development and manufacturing under one roof.

Successful tech transfer begins with early alignment, clear scope definition, and proactive risk management to ensure smooth progression from development to GMP manufacturing. By combining global expertise with local execution, Rentschler Biopharma delivers consistent quality, operational flexibility, and reduced risk for clients advancing complex therapies.

Explore how the sterile injectable manufacturing market is evolving to meet the dual demands of large-scale biologics and small-batch targeted therapies. In this video, Franco Negron of Simtra BioPharma Solutions shares insights on the trends, investments, and collaborations shaping the future of agile, resilient CDMO operations.

Conor Barry, PhD, Vice President and Global Head of R&D for Bioconjugates and Large Molecules at Piramal Pharma Solutions, discusses the evolving antibody-drug conjugate (ADC) landscape and how the company’s strategic investments and ADCelerate program are simplifying complex supply chains for global partners.

Mandy Vink, VP of Business Development at Codexis, explains how the company leverages over 20 years of expertise in small molecule APIs to advance biocatalysis across pharma.

Britton Jimenez, SVP of Sales and Marketing at Codexis, explains how the ECO Synthesis® Manufacturing Platform overcomes the limitations in scalability and sustainability that currently challenge the RNA therapeutics industry.

A long-term, trust-based CDMO partnership can support cell and gene therapy developers from early process development through GMP manufacturing and commercial supply.

Biopharmaceutical manufacturers can strategically choose between fed-batch and continuous manufacturing to balance scalability, flexibility, and market demand across the product lifecycle.

Discover how data governance and AI are transforming biologics manufacturing, from ensuring patient safety to improving process efficiency. Sundar Ramanan, PhD, MBA, Chief Quality Officer at Enzene, shares insights on leveraging data for quality, compliance, and collaboration between CDMOs and biotech innovators.

Scientific experts Katarzyna Darmochwal, PhD, and Carmen Sweeney, PhD, discuss the latest regulatory expectations for the analytical testing of biologics products. They explain why regulatory success depends not only on compliance, but also on the precision, reliability, and depth of scientific understanding behind every test method.

David McErlane, Group President of Biologics at Catalent, shares how integrated expertise in biologics helps simplify complexity, accelerate development, and deliver therapies to patients faster.

Saleem Farooqui of Fresenius Kabi explains how the company is addressing today’s pharmaceutical manufacturing needs. Watch this video to learn how these capabilities can help bring products to market successfully.

Biomanufacturing has relied on largely unchanged processes for decades, but today’s complex molecules require a smarter approach. Sundar Ramanan, PhD, MBA, Chief Quality Officer at Enzene, explains how fully-connected continuous manufacturing™ (FCCM™) enables this shift by integrating real-time monitoring, automation, and contamination control.

A new partnership between MilliporeSigma, the Life Science Business of Merck KGaA, Darmstadt, Germany, and Simtra BioPharma Solutions is delivering streamlined ADC solutions that simplify the supply chain, accelerate patient access to vital treatments, and offer customers expert support.

Rentschler Biopharma is evolving its CDMO capabilities through strategic partnerships, infrastructure investments, and sustainability initiatives to better support clients' complex biologics programs.

Steve Griffiths, Global VP of Business Development at GCS, discusses the essential environmental factors involved in cleanroom construction. Viewers will gain insight into the decisions that influence sustainability from selecting materials to optimizing energy use.

Christine S. Yore of Ecolab discusses products and solutions that help pharmaceutical companies address sustainability and cost challenges, along with other key issues in today’s market.

Innovative Fully-Connected Continuous Manufacturing™ technology and advanced facilities are revolutionizing biomanufacturing and driving cost efficiency, especially in monoclonal antibody production.

Christiane Bardroff, Chief Operating Officer and Patrick Meyer Global Head of Business Development—both at Rentschler Biopharma SE—share their insights into the company’s client-centric approach.

Benedikt von Braunmühl, CEO of Rentschler Biopharma, discusses the company's strategic shift toward biologics CDMO services.

Why are walk-on ceilings critical in cleanroom environments? This video breaks down their key benefits, types, and safety requirements to help you understand how they enhance cleanroom functionality. Learn about load considerations, installation challenges, and future innovations shaping the industry. Whether you're designing a cleanroom or upgrading an existing one, this video provides expert insights to guide your decisions.

Dr Himanshu Gadgil, CEO, Enzene Biosciences Ltd., describes the rationale for expanding its services, including its patented EnzeneX™ continuous manufacturing technology platform, to emerging innovative, US-based biotech firms looking to benefit from the in-depth expertise in continuous manufacturing.

Christoph Winterhalter, Chief Business Officer of AGC Biologics, highlights trends in single-use technology, the CDMO’s new fill-finish capabilities, facility expansions, the potential impact of the U.S. Biosecure Act, and the growing cell and gene market.